109 related articles for article (PubMed ID: 1941503)
1. Pharmacokinetics of pirarubicin in pediatric patients.
Nagasawa K; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K; Kosaka Y; Sano K; Murakami R; Nakamura H
J Pharmacobiodyn; 1991 Apr; 14(4):222-30. PubMed ID: 1941503
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
Robert J; David M; Huet S; Chauvergne J
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
[TBL] [Abstract][Full Text] [Related]
3. Distribution of pirarubicin in human blood.
Nagasawa K; Kitada N; Tsuji C; Ogawa M; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2866-9. PubMed ID: 1464120
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases.
Munck JN; Rougier P; Chabot GG; Ramirez LH; Bognel C; Lumbroso J; Herait P; Elias D; Lasser P; Gouyette A
Eur J Cancer; 1994; 30A(3):289-94. PubMed ID: 8204346
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.
Marchiset-Leca D; Leca FR; Galeani A; Noble A; Catalin J
Cancer Chemother Pharmacol; 1995; 36(3):239-43. PubMed ID: 7781145
[TBL] [Abstract][Full Text] [Related]
7. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin.
Sugiyama T; Sadzuka Y; Nagasawa K; Ohnishi N; Yokoyama T; Sonobe T
Jpn J Cancer Res; 1999 Jul; 90(7):775-80. PubMed ID: 10470291
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample.
Leca FR; Marchiset-Leca D; Galeani A; Noble A; Catalin J
Anticancer Drugs; 1998 Jul; 9(6):503-9. PubMed ID: 9877237
[TBL] [Abstract][Full Text] [Related]
11. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.
Marchiset-Leca D; Leca FR; Galeani A; Noble A; Iliadis A
Cancer Chemother Pharmacol; 1995; 36(3):233-8. PubMed ID: 7781144
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
13. Rapid and sensitive method for measuring the plasma concentration of doxorubicin and its metabolites.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H
Chem Pharm Bull (Tokyo); 2012; 60(3):391-6. PubMed ID: 22382422
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.
Munck JN; Riggi M; Rougier P; Chabot GG; Ramirez LH; Zhao Z; Bognel C; Ardouin P; Herait P; Gouyette A
Cancer Res; 1993 Apr; 53(7):1550-4. PubMed ID: 8453622
[TBL] [Abstract][Full Text] [Related]
15. Thermal enhancement of pirarubicin (THP-adriamycin) by mild hyperthermia in vitro.
Takahashi T; Mitsuhashi N; Sakurai H; Murata O; Kitamoto Y; Matsumoto H; Higuchi K; Niibe H
Int J Hyperthermia; 1997; 13(3):317-24. PubMed ID: 9222814
[TBL] [Abstract][Full Text] [Related]
16. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer.
Yamamoto Y; Nasu Y; Saika T; Akaeda T; Tsushima T; Kumon H
BJU Int; 2000 Nov; 86(7):802-4. PubMed ID: 11069404
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of pirarubicin in plasma and cerebrospinal fluid.
Morikawa N; Takeyama M; Mori T; Hori S
Ann Pharmacother; 1998 Feb; 32(2):269. PubMed ID: 9496418
[No Abstract] [Full Text] [Related]
18. [Pharmacokinetics of pirarubicin (THP-doxorubicin) in patients with cancer].
Robert J; David M; Huet S; Chauvergne J; Monnier A
Bull Cancer; 1989; 76(8):889-92. PubMed ID: 2620119
[No Abstract] [Full Text] [Related]
19. Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients.
Morris RG; Reece PA; Dale BM; Green RM; Kotasek D; Saccoia NC; Sage RE
Ther Drug Monit; 1989; 11(4):380-3. PubMed ID: 2741185
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
